K-ras ribozyme therapy (Baylor Research Institute)

N/A

Report date: 2025/05/14 13:52:06

Base Information

Drug NameK-ras ribozyme therapy (Baylor Research Institute)
Drug Alias NameK-ras ribozyme therapy (Berlex (Schering)/Baylor Research Institute)KRbz-ADVgene therapy (Berlex (Schering)/Baylor)ribozyme K-ras (Schering/Baylor)
ClassificationCell and gene therapy > Gene therapy > mRNASmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideSmall molecules > Nucleosides and nucleotide derivtives > Ribozyme
Mechanisms of ActionGTPase Ras inhibitors
TargetsGTPase Ras
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor Research Institute Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBaylor Research Institute LlcBerlex Biosciences Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A